COLORADO SPRINGS, Colo.,
March 3, 2015 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company
specializing in the development of cannabis-based medicine, today
announced two important developments: It launched its toll-free
call center in preparation for its multiple global product
launches, and CEO Raymond C. Dabney
recently shared his industry views in the Chicago HR Examiner.
In the article, Dabney answers questions from columnist
Pam C. Waits about leading a company
in an industry that is too new for a blueprint. Dabney discussed
the goals and direction of the company, how it is helping build
awareness for the effectiveness of medicinal cannabis and how it is
working to bring cannabinoid-based medicines to the forefront of
the healthcare community through credible research and
development.
"The reader response to my Q&A with Raymond has been
overwhelming," said Waits, who has been writing for Chicago
Examiner since 2011. "His focus and serious approach for
leading a company without an industry blueprint is impressive
and insightful."
To read the Q&A in its entirety, click here:
http://exm.nr/1F78MSR
"We have been overwhelmed with phone calls and emails in regards
to our pre-clinical studies, state-by-state initiatives, new
product releases, cannabinoid treatment education, and project
partnerships," said Dabney. "This shows the general public interest
and momentum toward understanding the use of cannabinoids. It is
very difficult to reach out to everyone while progressing our drug
development programs to meet the critical growing demand. We are
very excited to report that all is moving much stronger and faster
than we could have anticipated."
The new call center, Dabney said, is an opportunity for an eager
public and healthcare professionals to find out more about the
goals of Cannabis Science, the impressive credentials of the CBIS
scientific and medical leaders and the company's current and future
pre-clinical studies and upcoming product launches in the U.S. and
abroad.
He said the Cannabis Science Research Foundation's "state by
state initiatives" are growing quickly as the company navigates the
changing laws and public perception.
"California has given us some
exciting new developments as we await our final product approvals
and manufacturing," Dabney said. "Our aggressive schedule has lead
to exciting events we believe will greatly benefit those of
interest, as our final product launch date is approaching rapidly.
I believe this will be well worth the wait."
"Michigan has now matured to
the point of multiplied returns; I strongly believe this will be
another very important state for the company and the general
public. Our New York initiatives
are slowly coming to a head as we develop the required teams to
handle such a large market. We also have some very special
relationships in Washington DC. My
frequent travel there has been a serious eye opener and has given
us the ability to move in a circle of influence as never before. We
also have several other state targets that are no less important
from a drug development and delivery standpoint. We are constantly
sorting through new opportunities to advance our programs and
deliver at an accelerated rate. We look forward to hearing from the
public, investors and the medical community via our new call
center."
In the company's new Drug Development Initiatives, Dabney said
the company's recent focus has been on continuing to develop a
world-class research team and operational structures capable of
meeting a growing global demand while launching pre-clinical
studies in Europe, pre-clinical
initiatives in the United States
and other global initiatives. The company has also successfully
initiated its African healthcare initiatives, targeting key issues
and international concerns. As the newly appointed Vice Chair of
the recently launched Constituency for Africa (CFA) Africa Healthcare Infrastructure
Committee, Dabney joins retired U.S. Assistant Surgeon General Dr.
Roscoe M. Moore Jr., who is CFA
Interim Chair and Chair of the Africa Healthcare Infrastructure
Committee.
"We are looking forward to announcing some more exciting
groundbreaking news as we progress through these international
landscapes favorably," Dabney said.
"Scholars, economists, industrialist and high-ranking government
officials worldwide are all well aware of how important the
redevelopment of this Continent is right now," Dabney said. "We
have a special interest in strengthening the healthcare
infrastructure to assist in the reconstruction of such an
important continent. Again, I am greatly honored to be brought
in so close among such great leaders, to help make a difference in
Africa right now. We are rapidly
determining how the Cannabis Science team can help make an
immediate and long-term difference."
Dabney added that "between those activities, product launches,
the publicity we've been receiving and the new toll-free line,
we're firing on all cylinders. We are rapidly adding to the team as
we expand our international drug development programs. We greatly
appreciate your encouragement as we enjoy the growing pains as we
progress forward with your support."
The company formally invites the public and healthcare
professionals to call 1.888.889.0888 toll-free to speak with its
team to learn more about the company and its focus to develop
groundbreaking cannabinoid-based treatments.
"We thank you wholeheartedly for your interest and support of
our critical-ailment drug development programs, research,
education, and philanthropic initiatives," Dabney said. "We also
look forward to seeing you in our Patient Access Center sharing
your medical cannabinoid stories and important information with the
world."
About Cannabis Science, Inc. Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches.
Forward-Looking Statements This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Media Contact:
VAN STONE PUBLICITY
Carrol Van
Stone
carrol@vanstonepublicity.com
Tel: 304-671-0244
Cannabis Science, Inc.
Raymond
C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
Chad S. Johnson, Esq.
Director, COO & General Counsel
info@cannabisscience.com
Tel: 1.888.889.0888
www.cannabisscience.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cbis-momentum-continues-company-opens-call-center-in-preparation-for-new-product-releases--ceo-shares-his-impressive-and-insightful-views-with-columnist-300044494.html
SOURCE Cannabis Science, Inc.